Analysts expect Molecular Partners Ag to report revenue of 0.00 for Q3 26, against a range of 0.00 to 0.00. The most recent reported quarter, Q2 26, came in at 0.00.
| Metric | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 | Q1 28 | Q2 28 | Q3 28 | Q4 28 | Q1 29 | Q2 29 | Q3 29 | Q4 29 | Q1 30 | Q2 30 | Q3 30 | Q4 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | 804,180.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - | - | - | - | - | - | - | - | ||||||||||
| High Estimate | 464,417.33 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 56,411.77 | 59,229.95 | -27,808.25 | -84,886.18 | 64,648.83 | 105,227.18 | ||||||||||
| Low Estimate | 413,556.31 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 52,126.15 | 49,052.09 | -30,387.19 | -93,043.92 | 56,145.29 | 95,257.86 | ||||||||||
| Consensus Estimate | 438,986.82 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 54,268.96 | 54,141.02 | -29,097.72 | -88,965.05 | 60,397.06 | 100,242.52 |
Analysts expect Molecular Partners Ag to report earnings per share of -0.45 for Q3 26, against a range of -0.48 to -0.42. The most recent reported quarter, Q2 26, came in at -0.44, a 4.3% beat against the -0.46 consensus.
| Metric | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | -0.56 | -0.36 | -0.54 | -0.69 | -0.42 | -0.44 | -0.43 | -0.44 | - | - | - | - |
| High Estimate | -0.62 | -0.38 | -0.44 | -0.48 | -0.45 | -0.41 | -0.38 | -0.44 | -0.42 | -0.37 | -0.42 | -0.38 |
| Low Estimate | -0.68 | -0.46 | -0.46 | -0.52 | -0.51 | -0.45 | -0.44 | -0.48 | -0.48 | -0.41 | -0.46 | -0.42 |
| Consensus Estimate | -0.65 | -0.42 | -0.45 | -0.50 | -0.48 | -0.43 | -0.41 | -0.46 | -0.45 | -0.39 | -0.44 | -0.40 |